On 12 April 2010 JSC Grindeks has received the notification on obtaining significant holding from OJSC “Pharmstandart”. “Pharmstandart’s” total holdings in the security of JSC Grindeks currently amount to 11.3 % of the outstanding shares.

Grindeks Chairman of the Board Janis Romanovskis: “OJSC “Pharmstandart” is the leading Russian pharmaceutical company and since 2008 is one of the most important cooperation partners of Grindeks that promotes and sells our brand product Mildrontate®. OJSC “Pharmstandart” as one of the biggest shareholders of Grindeks will strengthen our positions in Russia and provide new business opportunities.”

In the attachment: Notification from “Pharmstandart” on 4 (four) pages.

Further information:
Laila Kļaviņa
Head of the Communications Department
JSC Grindeks
Phones: (+371) 67083370, (+371) 29256012

Fax: (+371) 67083505
e-mail: laila.klavina@grindeks.lv

Notification from "Pharmstandart" (325 KB)